Effects of aqueous extracts of dried calyx of sour tea (Hibiscus sabdariffa L.) on polygenic dyslipidemia: A randomized clinical trial

Document Type : Original Research Article


1 National Nutrition and Food Technology Research Institute, Faculty of Nutrition & Food Technology Shahid Beheshti University of Medical Sciences, Iran

2 Department of Health Education and Promotion, Gonabad University of Medical Sciences, Gonabad, Iran

3 Food and Drug Deputy, Mashhad University of Medical Sciences, Iran

4 Department of Epidemiology, College of Public Health Shahid Beheshti University of Medical Sciences, Iran

5 Ebnesina Hospital, Mashhad University of Medical Sciences, Iran

6 Department of Traditional Medicine Shahid Beheshti University of Medical Sciences, Iran

7 Department of Humanities, Gonabad University of Medical Sciences, Iran

8 Natural Products & medicinal plants Research Center, North Khorsan University of Medical Sciences, Bojnurd, Iran


Objective: Dyslipidemia has been considered as a major risk factor for coronary heart disease. Alternative medicine has a significant role in treatment of dyslipidemia. There are controversial findings regarding the effects of sour tea on dyslipidemia. The aim of this study was to evaluate the impact of aqueous extract of dried calyx of sour tea on polygenic dyslipidemia.
Materials and Methods: This clinical trial was done on 43 adults (30-60 years old) with polygenic dyslipidemia that were randomly assigned to the intervention and control groups. The control group was trained in lifestyle modifications at baseline. The intervention group was trained for lifestyle modifications at baseline and received two cups of sour tea daily, and both groups were followed up for 12 weeks. Lipid profile was evaluated at baseline, and six and 12 weeks following the intervention. In addition, dietary and physical activity assessed at baseline for twelve weeks.
Results: Mean concentration of total cholesterol, HDL-C and LDL-C significantly decreased by up to 9.46%, 8.33%, and 9.80%, respectively, after 12 weeks in the intervention group in comparison to their baseline values. However, LDL-C/HDL-C ratio significantly increased  by up to 3.15%, following 12 weeks in the control group in comparison to their baseline values. This study showed no difference in lipid profiles between the two groups, except for HDL-C concentrations.
Conclusion: sour tea may have significant positive effects on lipid profile of polygenic dyslipidemia subjects and these effect might be attributed to its anthocyanins and inflation factor content. Therefore, sour tea intake with recommended dietary patterns and physical activity can be useful in regulation of lipid profile in patients with polygenic dyslipidemia.


Main Subjects

Azizi F, Rahmani M, Emami H, Mirmiran P, Hajipour R, Madjid M. 2002. Cardiovascular risk factors in an Iranian urban population: Tehran lipid and glucose study (phase 1). Soz Praventivmed, 47:408-426.
Ali B, Al Wabel N, Blunden G. 2005. Phytochemical, pharmacological and toxicological aspects of Hibiscus sabdariffa L.: a review. Phytother RES, 19:369-375.
Ajay M, Chai HJ, Mustafa AM, Gilani AH, Mustafa MR. 2007. Mechanisms of the anti-hypertensive effect of Hibiscus sabdariffa L. calyces. J Ethnopharmacol,109:388-393.
Al-Noory AS, Amreen AN, Hymoor S. 2013. Antihyperlipidemic effects of ginger extracts in alloxan-induced diabetes and propylthiouracil-induced hypothyroidism in (rats). Pharmacognosy Res, 5:157-161
Asghari G, Rezazadeh A, Hosseini-Esfahani F, Mehrabi Y, Mirmiran P, Azizi F. 2012. Reliability, comparative validity and stability of dietary patterns derived from an FFQ in the Tehran Lipid and Glucose Study. BJN, 08:1109-1117.
British Pharmacopoeia Commission, Aug 21, 2009. 
Derosa G, Bonaventura A, Bianchi L, Romano D, D'Angelo A, Fogari E, Maffioli P. 2013.  Berberis aristata/Silybum marianum fixed combination on lipid profile and insulin secretion in dyslipidemic patients. EOBT J, 13:1495-1506
Esfahani F, Asghari G, Mirmiran P, Azizi, F. 2010. Reproducibility and relative validity of food group intake in a food frequency questionnaire developed for the Tehran Lipid and Glucose Study. J Epidemiol, 20:150-158.
Goff DC J, Bertoni A, Kramer H, Bonds D, Blumenthal R, Tsai M, Psaty, B. 2006. Dyslipidemia prevalence, treatment, and control in the Multi-Ethnic Study of Atherosclerosis (MESA): gender, ethnicity, and coronary artery calcium. Circulation, 113: 647-656.
Guidelines for Data Processing and Analysis of the International Physical Activity Questionnaire (IPAQ). Short and Long Forms. www.ipaq.ki.se/scoring.pdf; Nov 2005 [5 Jan. 2012].
Gurrola-Diaz C, Garcia-Lopez P, Sanchez-Enriquez S, Troyo-Sanroman R, Andrade-Gonzalez I, Gomez-Leyva J. 2010. Effects of Hibiscus sabdariffa extract powder and preventive treatment (diet) on the lipid profiles of patients with metabolic syndrome (MeSy). Phytomedicine, 17:500-5.
Haji Faraji M, Haji Tarkhani A. 1999. The effect of sour tea (Hibiscus sabdariffa) on essential hypertension. J Ethnopharmacol, 65:231-236.
Hirunpanich V, Utaipat A, Morales N, Bunyapraphatsara N, Sato H, Herunsale, A, Suthisisang C. 2006. Hypocholesterolemic and antioxidant effects of aqueous extracts from the dried calyx of Hibiscus sabdariffa L. in hypercholesterolemic rats. J. Ethnopharmacol, 103:252-260.
Hopkins A, Lamm M, Funk J, Ritenbaugh C. 2013. Hibiscus sabdariffa L. in the treatment of hypertension and hyperlipidemia: A comprehensive review of animal and human studies. Fitoterapia, 85:84-94
Lin T-L, Lin H-H, Chen C-C, Lin M-C, Chou M-C, Wang, C.-J. 2007. Hibiscus sabdariffa extract reduces serum cholesterol in men and women. Nutrition research New York, NY, 27:140-145.
Luz Fernandez M, Webb D. 2008. The LDL to HDL Cholesterol Ratio as a Valuable Tool to Evaluate Coronary Heart Disease Risk. Journal of the American College of Nutrition, 27:1–5.
Maffo Tazoho G, Etame Loe G, Pankoui M, Joel B, Feukeng M, Fotso Kuate, H, Tchouanguep Mbiapo F, Gouado I. 2011. Effect of “Foléré” Juice (Calyx of Hibiscus sabdariffa Lin) on Some Biochemical Parameters in Humans. P J N, 10: 755-759.
Mahadevan N, Shivali A, Kamboj P. 2009. Hibiscus sabdariffa Linn: an overview. Nat Prod Rad, 8:77-83.
Mohagheghi A, Maghsoud S, Khashayar P, Ghazi-Khansari M. 2011. The effect of hibiscus sabdariffa on lipid profile, creatinine, and serum electrolytes: a randomized clinical trial. ISRN Gastroenterol, 976019.
Mozaffarian D, Wilson P, Kannel W. 2008. Beyond established and novel risk factors: lifestyle risk factors for cardiovascular disease. Circulation, 117: 3031-3038.
Mozaffari-Khosravi H, Jalali-Khanabadi B, Afkhami-Ardekani M, Fatehi F. 2009. Effects of sour tea (Hibiscus sabdariffa) on lipid profile and lipoproteins in patients with type II diabetes. J Altern Complement Med, 15:899-903.
Ochani PC, D'Mello P. 2009. Antioxidant and antihyperlipidemic activity of Hibiscus sabdariffa Linn. Leaves and calyces extracts in rats. Indian J Exp Bio, l47:276-282.
Pagana K D, Pagana P. 2009. Mosby's Manual of Diagnostic and Laboratory Tests. 9e.
Ramirez-Rodrigues M, Plaza M, Azeredo A, Balaban M, Marshall M. 2011. Physicochemical and phytochemical properties of cold and hot water extraction from Hibiscus sabdariffa. J Food Sci, 76:428-435.
Sabzghabaee AM, Ataei E, Kelishadi R, Ghannadi A, Soltani R, Badri S, Shirani S. 2013. Effect of Hibiscus sabdariffa Calices on Dyslipidemia in Obese Adolescents: A Triple-masked Randomized Controlled Trial. Mater Sociomed, 25:76-79.
Sayago-Ayerdi S, Arranz S, Serrano J, Goni I. 2007. Dietary fiber content and associated antioxidant compounds in Roselle flower (Hibiscus sabdariffa L.) beverage. J Agric Food Chem, 55:7886-7890.
Tolonen H, Kell U, Ferrario M, Evans A. 2005. Prevalence, awareness and treatment of hypercholesterolaemia in 32 populations: results from the WHO MONICA Project. Int J Epidemiol, 34:181-192.
Varady K, Jones P. 2005. Combination diet and exercise interventions for the treatment of dyslipidemia: an effective preliminary strategy to lower cholesterol levels. J Nutr, 135: 1829-1835.
World Health Organization. 1998. Quality control methods for medicinal plant materials. Geneva: World Health Organization.